Physician profile
Aaron D Brown
NPI 1730175456
$3,660.78
in general payments reported to CMS, 2019-2025
16 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,520 · 2020: $335 · 2021: $459 · 2022: $330 · 2023: $463 · 2024: $139 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $767 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $767.46 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $564.05 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $548.83 | 2021-2025 | Qulipta |
| Lilly USA, LLC | $417.54 | 2019-2025 | Mounjaro |
| Janssen Pharmaceuticals, INC | $402.18 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $333.22 | 2019-2025 | Breztri, Airsupra |
| Genzyme Corporation | $240.00 | 2019-2020 | |
| Pfizer INC. | $226.51 | 2020-2025 | |
| Exact Sciences Corporation | $213.23 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.57 | 2019 | |
| Sanofi-Aventis U.S. LLC | $118.77 | 2022 | |
| Allergan, INC. | $116.64 | 2019 | |
| Novartis Pharmaceuticals Corporation | $91.10 | 2019 | |
| Amarin Pharma, INC. | $90.69 | 2019 | |
| Supernus Pharmaceuticals, INC. | $61.56 | 2020-2021 | |
| Glaxosmithkline, LLC. | $25.62 | 2025 | Trelegy Ellipta |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $13.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.